Literature DB >> 32122448

Prevalence and management of aspirin hypersensitivity in a cardiology practice.

Gabriela M Orgeron1, Ruby Havistin1, Laura S Hahn1, John Wang1, Candace Crichlow1, Marc Mugmon1, Anshul Mahajan1, Anthony Jourdan2, Sudhir Sekhsaria1.   

Abstract

Background: Data are lacking with concern to the prevalence and management of aspirin (ASA) hypersensitivity. Objective: To study the prevalence, different types of reactions, and implications for clinical management of ASA hypersensitivity in a cardiology practice.
Methods: We conducted an electronic medical record review of 11,375 individuals, 5052 (44%) in the ambulatory setting, and 6323 (56%) admitted for percutaneous coronary intervention (PCI), from January 2012 to December 2013.
Results: The prevalence of ASA hypersensitivity was 1.88% (n = 214). Skin reactions were the most common (40 [19%]), followed by angioedema (10 [4.6%]), respiratory (9 [4.2%]), and anaphylaxis (6 [2.8%]). No records were found for 74 patients (34.5%), and 69 patients (32.2%) were mistakenly labeled as allergic for having gastrointestinal symptoms. Of the 214 patients who had documented ASA hypersensitivity, 108 individuals (50.46%) had coronary artery disease. The medications at discharge were the following: ASA (30 [14%]), thienopyridine (48 [22%]), a combination of ASA and thienopyridine (13 [6%]), anticoagulation only (26 [12%]), and no antiplatelet (97 [43%]).
Conclusion: ASA hypersensitivity is often not documented correctly or is often misdiagnosed or not appropriately managed. There is a need for improved management of ASA hypersensitivity, including appropriate referral for ASA desensitization and combating unnecessary avoidance in patients with intolerance due to adverse effects.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32122448     DOI: 10.2500/aap.2020.41.190032

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  1 in total

1.  Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Authors:  Yikai Zhao; Peng Zhou; Wen Gao; Haoxuan Zhong; Yufei Chen; Wei Chen; Maieryemu Waresi; Kun Xie; Haiming Shi; Hui Gong; Guibin He; Zhaohui Qiu; Xinping Luo; Jian Li
Journal:  Clin Cardiol       Date:  2022-02-04       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.